J Shamash
Overview
Explore the profile of J Shamash including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
407
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haq K, Chia D, Haroon U, Oluwole-Ojo A, Reeves F, Verma H, et al.
J Robot Surg
. 2025 Mar;
19(1):111.
PMID: 40067494
The objective of the study is to define selection parameters for RRPLND and evaluate the outcomes from cases selected via this method. Patients undergoing RRPLND from 2017 to 2023 (n ...
2.
Newton C, Murali K, Ahmad A, Hockings H, Graham R, Liberale V, et al.
Eur J Cancer
. 2019 Apr;
113:19-27.
PMID: 30954883
Background: Adult guidelines recommend BEP (bleomycin, etoposide, cisplatin) for all ovarian germ cell tumours, causing debilitating toxicities in young patients who will survive long term. Paediatricians successfully reduce toxicities by...
3.
Crusz S, Radunovic A, Shepherd S, Shah S, Newey V, Phillips M, et al.
Eur J Cancer
. 2018 Aug;
102:49-51.
PMID: 30138772
No abstract available.
4.
Shamash J, Sarker S, Huddart R, Harland S, Joffe J, Mazhar D, et al.
Ann Oncol
. 2017 Mar;
28(6):1333-1338.
PMID: 28327896
Background: Bleomycin is an integral part of combination chemotherapy in germ cell tumours. Pulmonary toxicity often necessitates drug cessation and death occurs in 1%-2% of patients. A continuous infusion of...
5.
6.
Powles T, Kayani I, Sharpe K, Lim L, Peters J, Stewart G, et al.
Ann Oncol
. 2013 Apr;
24(8):2098-103.
PMID: 23579815
Background: Vascular endothelial growth factor (VEGF)-targeted therapy is administered continuously until progression in metastatic clear cell renal cancer (mRCC). The role of intermittent therapy is under investigation. Preclinical data raise...
7.
Payne S, Krell J, Wilson P, Ansell W, Frampton A, Stebbing J, et al.
Lung Cancer
. 2013 Feb;
80(2):228-9.
PMID: 23380223
Background: Thymomas and thymic carcinomas, although uncommon, constitute a significant proportion of anterior mediastinal tumours. Systemic chemotherapy is the mainstay of treatment for inoperable or recurrent disease, but immunosuppressive therapy...
8.
Rimmer Y, Chester J, Joffe J, Stark D, Shamash J, Powles T, et al.
Br J Cancer
. 2011 Aug;
105(6):766-72.
PMID: 21847130
Background: We used bleomycin, etoposide, cisplatin (BEP), the most effective regimen in the treatment of germ cell tumours (GCTs) and increased dose-density by using pegfilgrastim to shorten cycle length. Our...
9.
Shamash J, Powles T, Sarker S, Protheroe A, Mithal N, Mills R, et al.
Br J Cancer
. 2011 Feb;
104(4):620-8.
PMID: 21285990
Background: The role of further hormone therapy in castration-resistant prostate cancer (CRPC) remains unclear. We performed a multi-centre randomised phase III study comparing the use of Dexamethasone, Aspirin, and immediate...
10.
Powles T, Kayani I, Blank C, Chowdhury S, Horenblas S, Peters J, et al.
Ann Oncol
. 2011 Jan;
22(5):1041-1047.
PMID: 21242586
Background: The safety and efficacy of upfront sunitinib, before nephrectomy in metastatic clear cell renal cancer (mCRC), has not been prospectively evaluated. Methods: Two prospective single-arm phase II studies investigated...